Lactate abnormalities during intravenous linezolid therapy in hospitalized children: a brief report
European Journal of Pediatrics, vol.185, no.6, 2026 (SCI-Expanded, Scopus)
- Publication Type: Article / Editorial Material
- Volume: 185 Issue: 6
- Publication Date: 2026
- Doi Number: 10.1007/s00431-026-07064-5
- Journal Name: European Journal of Pediatrics
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE
- Open Archive Collection: AVESIS Open Access Collection
- Hacettepe University Affiliated: Yes
Abstract
Linezolid is commonly used in children for the treatment of severe gram-positive infections; however, data on metabolic adverse effects remain limited. We evaluated lactate abnormalities in pediatric patients receiving intravenous linezolid. Among 215 children, hyperlactatemia/lactic acidosis occurred in 55.8%. Hyperlactatemia and/or lactic acidosis tended to develop early after treatment initiation and was more frequently observed in younger children and in those with complex underlying conditions, including neurometabolic and hemato-oncologic disorders. These findings suggest that host-related factors may influence susceptibility to lactate disturbances during linezolid therapy and support careful clinical monitoring in selected pediatric populations.